IOWA | Health and Human Services

Vaccines for Children (VFC) Program MenABCWY Penmenvy Vaccine Summary October 2, 2025

Purpose

Effective October 2, 2025, Penmenvy, a MenABCWY vaccine manufactured by GlaxoSmithKline (GSK), is available to order through the Iowa VFC Program.

Food and Drug Administration (FDA)

On February 14, 2025, the FDA approved GlaxoSmithKline's MenABCWY vaccine (Penmenvy) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. Penmenvy is approved for use in individuals 10 through 25 years of age.

On April 16,2025, CDC's Advisory Committee on Immunization Practices (ACIP) recommended GSK's MenABCWY Penmenvy vaccine may be used as an option when both MenACWY and MenB are indicated at the same visit. The ACIP recommendation for Penmenvy was adopted by the HHS Secretary on June 25, 2025, and is now an official recommendation of the CDC.

VFC Program Resolution

The Federal VFC Program follows the ACIP recommendations for the use of MenABCWY vaccines as an option to vaccinate VFC eligible children ages 10 years through 18 years.

ACIP Recommended Schedule for MenABCWY Vaccine (Penmenvy)

Penmenvy vaccine may be used when both MenACWY and MenB vaccine are indicated at the same visit for:

- healthy individuals aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccination, and
- individuals aged 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines.

The licensed meningococcal B component vaccines are not interchangeable by manufacturer. The B component of the MenABCWY Penmenvy vaccine is Bexsero. Administration of a B component vaccine (MenB or MenABCWY) requires that subsequent B component vaccine doses be from the same manufacturer. The minimum interval for GSK's MenABCWY vaccine (Penmenvy) is 6 months.

Individuals at increased risk of meningococcal disease who are recommended to receive additional doses of MenACWY and MenB less than 6 months after a dose of pentavalent meningococcal vaccine should instead receive separate MenACWY and MenB vaccine. The MenB vaccine should be from the same manufacturer as previous doses.

Recommended Dosage and Administration

- The recommended dose is 0.5mL administered as an intramuscular injection. It is supplied as one vial of lyophilized MenACWY component (powder), and one prefilled syringe of MenB component (liquid) which must be combined before administration. Invert the prefilled syringe multiple times to form a homogeneous suspension. Do not use the prefilled syringe of the MenB component if it cannot be resuspended. Connect a sterile needle to the prefilled syringe. Cleanse the vial stopper and slowly transfer the contents of the syringe into the vial containing the lyophilized component. Without removing the needle from the vial, swirl the vial gently until the powder is completely dissolved. Do not invert the vial or shake vigorously. Penmenvy is a white opalescent suspension after mixing. Do not administer if particulate matter or discoloration is visible.
- MenABCWY is approved for use in individuals 10 through 25 years of age and is given as a two-dose series with a minimum interval of 6 months between doses.

Refer to the package insert for further details: PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for injectable suspension, for intramuscular use. MenABCWY (Penmenvy) vaccine can be administered at the same time as other vaccines.

Vaccine Storage and Handling

Storage Before Reconstitution

- Store refrigerated at 2°C - 8°C (36°F - 46°F) in the original carton to protect from light.
- Do not freeze.
- Do not use product if exposed to out-of-range temperatures.
- Do not use after expiration date shown on the label.

Storage After Reconstitution

- Use immediately after reconstitution

Precautions

- Moderate or severe acute illness with or without fever

Contraindications

- Severe allergic reaction (e.g., anaphylaxis) to any vaccine component or following a prior dose
- Severe allergic reaction to a diphtheria toxoid-containing vaccine

Pregnancy and Breastfeeding

Few data exist on the use of Penmenvy during pregnancy or while breastfeeding. Limited data are available for MenB vaccination during pregnancy and vaccination with MenB should be deferred unless the pregnant person is at increased risk for acquiring meningococcal disease, and, after consultation with the healthcare provider, the benefits of vaccination are considered to outweigh the potential risks. When MenACWY is indicated, persons who are pregnant or breastfeeding should receive MenACWY-CRM (Menveo, GSK) or MenACWY-TT (MenQuadfi, Sanofi Pasteur).

Reporting of Adverse Events

Adverse events following administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (1-800-822-7967) or online (https://vaers.hhs.gov).

CPT Code

90624